JANX at a glance
Janux Therapeutics, Inc. (JANX, SEC CIK 1817713) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as July 31, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Janux Therapeutics, Inc. (JANX) reported revenue of $10.0 million (down 5.6% from FY2024) and a net loss of $113.6 million. Diluted EPS was -$1.83.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Janux Therapeutics, Inc. (JANX) shares worth $372.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $10.0M
- −5.6% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $372.1M · +0 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Collaboration revenue $9.3M, down $0.7M YoY, BMS revenue offsetting lower Merck revenue
- Net loss $21.6M vs $24.3M YoY, operating loss $31.3M vs $35.3M
- JANX007 highest R&D spend at $6.7M, up $0.5M; JANX013 lowest at $1.0M, down $2.6M
- Cash, restricted cash and short-term investments $946.5M; operating cash use $25.0M vs $53.7M YoY
- Existing liquidity expected to fund operations and capital expenditures through at least the next 12 months; clinical spending headwind
Risk Factors
- Clinical discontinuation of JANX008 in April 2026 after Phase 1a activity proved insufficient versus other pipeline programs
- Regulatory risk: U.S. FDA staffing cuts may delay IND reviews, guidance and future approvals
- Manufacturing concentration: BDS for each product candidate expected to rely on single-source suppliers
- Liquidity risk: $945.7 million in cash, equivalents and short-term investments funds operations for at least 12 months
- Competitive risk: larger biopharmaceutical companies may develop safer, more effective or cheaper immunotherapies faster
AI summary of the JANX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Investor-relevant figures and management commentary contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 net loss $21.6M, or $0.34 per share, improved from $24.3M, or $0.39, year over year
- Cash, equivalents and short-term investments $945.7M, down from $966.6M at December 31, 2025, supporting multiple clinical programs
Item EX-99.1: Item EX-99.1
- Q2 collaboration revenue $10.3M; net loss narrowed to $22.0M from $33.9M year over year
- Cash, equivalents and short-term investments $970.9M, supporting multiple clinical programs
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Press release attached as Exhibit 99.1, containing the substantive financial details
Item 8.01: Other Events
- Chief Medical Officer William Go, M.D., Ph.D. departed June 23, 2026, in a termination without “Cause”
- Successor search underway, with existing clinical leadership assuming interim responsibilities
AI summaries of JANX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for JANX
Don't miss the next JANX filing
- Alerts as it files. A push when JANX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut JANX, by share count.
- Ask anything. An AI agent that reads every JANX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Campbell David Alan | G | Jul 31, 2026 | 123,840 | - |
| Campbell David Alan | M | Jul 8, 2026 | 7,000 | - |
| Campbell David Alan | M | Jul 8, 2026 | 7,000 | $4.21 |
| Kung Winston | A | Jun 11, 2026 | 15,500 | - |
| CAPPS VICKIE L | A | Jun 11, 2026 | 5,500 | - |
| CAPPS VICKIE L | A | Jun 11, 2026 | 15,500 | - |
| Simson Jake | A | Jun 11, 2026 | 5,500 | - |
| Barrett Ronald W | A | Jun 11, 2026 | 15,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $10.6M | $10.0M |
| Operating Income | - | -$98.8M | -$157.7M |
| Net Income | -$58.3M | -$69.0M | -$113.6M |
| Op. Margin | - | -933.6% | -1576.7% |
| Net Margin | - | -651.6% | -1136.3% |
| Balance Sheet | |||
| Total Assets | $380.4M | $1.1B | $1.0B |
| Equity | - | $1.0B | $956.8M |
| ROE | - | -6.7% | -11.9% |
| Per Share | |||
| EPS | $-1.32 | $-1.28 | $-1.83 |
| Cash Flow | |||
| Operating CF | - | -$43.8M | -$82.2M |
| CapEx | $1.9M | $359K | $1.0M |
Source: XBRL data in Janux Therapeutics, Inc. (JANX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate JANX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $372.1M |
| Q2 2026 | 25 | $353.5M |
| Q1 2026 | 24 | $245.0M |
| Q4 2025 | 20 | $283.1M |
| Q3 2025 | 22 | $571.3M |
| Q2 2025 | 23 | $532.7M |
| Q1 2025 | 19 | $458.3M |
| Q4 2024 | 16 | $797.3M |
- Two Sigma Investments+638.2K (+53%)
- D.E. Shaw & Co+412.9K (+38%)
- BlackRock+400.1K (+7%)
- Vanguard Capital Management LLC+295.8K (+16%)
- AQR Capital Management+142.1K (+132%)
- Citadel Advisors LLC−704.2K (-59%)
- State Street Corp−694.0K (-23%)
- Bank of America Corp−404.1K (-44%)
- Millennium Management−285.4K (-57%)
- Citigroup−40.7K (-58%)
- Ameriprise Financial+749.1K
- Fifth Third Bancorp+25
- FMR LLC (Fidelity)−2.41M
- Allstate−18.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 174 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
JANX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| SC 13G | May 12, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 29, 2026 | - | - | |
| SC 13G | Apr 29, 2026 | - | - | |
| 8-K | Apr 28, 2026 | - | Analysis | - |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
JANX SEC filings: frequently asked questions
Which institutions hold JANX stock?
As of September 30, 2026, the largest Janux Therapeutics, Inc. (JANX) holders among the 13F filers tracked by SignalX were BlackRock ($112.9 million), State Street Corp ($39.9 million), Vanguard Capital Management LLC ($37.2 million), Two Sigma Investments ($31.9 million), D.E. Shaw & Co ($26.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was JANX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Janux Therapeutics, Inc. (JANX) reported revenue of $10.0 million (down 5.6% from FY2024) and a net loss of $113.6 million. Diluted EPS was -$1.83. The figures come from the XBRL data in the 10-K.
What did JANX report in its latest 8-K?
Janux Therapeutics, Inc. (JANX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.
What are the latest JANX SEC filings?
Janux Therapeutics, Inc. (JANX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on July 31, 2026.
What is JANX's SEC CIK number?
Janux Therapeutics, Inc. (JANX)'s SEC Central Index Key (CIK) is 1817713. EDGAR lists every JANX filing under that number.
Ask anything about JANX
The research agent reads JANX's filings, financials, insider trades and 13F holders, then answers with sources.